The pharmacokinetics and tolerability of a single 8-mg oral dose of rosiglitazone, an anti-diabetic agent, were compared in 10 long-term haemodialysis patients and 10 healthy volunteers.
Introduction
Diabetic nephropathy is a common cause of end-stage renal disease (ESRD), 1 -3 affecting up to 21% of patients with type 2 diabetes mellitus. 4, 5 Over the past 2 decades, the incidence of ESRD in patients with diabetes has steadily increased, particularly in the USA, Japan and western Europe. 6 In many nations, diabetic nephropathy is now the leading cause of ESRD and kidney transplantation. 6, 7 End-stage renal disease is associated with marked alterations in the pharmacokinetics of many drugs, not only as a result of reduced renal clearance but also because of changes in metabolic activity, bioavailability, volume of distribution and plasma protein binding. 8, 9 ESRD is known to alter the pharmacokinetics of a wide range of anti-diabetic agents, 10 including metformin 11 and sulphonylureas. 10, 12 It is therefore important to assess the pharmaco- 13 Rosiglitazone is metabolized primarily via Ndemethylation and aromatic hydroxylation followed by conjugation. 14 The main route of excretion is in the form of metabolites in urine; no intact rosiglitazone is excreted in urine or faeces. 15 The primary objective of this study was to estimate the pharmacokinetics, safety and tolerability of a single 8-mg oral dose of rosiglitazone in haemodialysis-dependent patients with ESRD on non-dialysis days in comparison with healthy volunteers. A secondary objective was to determine the effect of the haemodialysis procedure itself on plasma drug concentrations.
Patients and methods

STUDY DESIGN
An open-label, single-dose, parallel-group study was conducted in 10 haemodialysisdependent patient volunteers with ESRD and 10 healthy volunteers with normal renal function. All participants provided written informed consent. The study was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki (1996 amendment). Both the protocol and statement of informed consent were approved by the Western Institutional Review Board, Olympia, WA, USA. The study was performed at the SmithKline Beecham Clinical Pharmacology Unit, Presbyterian Medical Center of Philadelphia, University of Pennsylvania Health System, Philadelphia, PA, USA. Haemodialysis treatments were conducted at GAMBRO Healthcare/Dialysis Center, Philadelphia, PA, USA.
INCLUSION/EXCLUSION CRITERIA
Eligible individuals were men or women (non-pregnant, non-lactating) aged 18 -65 years, with a body weight of ≥ 50 kg (within 30% of ideal). To be eligible, women had to have a negative serum pregnancy test. All haemodialysis-dependent patients had to have been clinically stable on maintenance haemodialysis for at least 3 months and able to tolerate a haemodialysis treatment lasting 4 h with blood flow rates of 400 -500 ml/min. Healthy volunteers had to have a negative urine drug screen, a satisfactory medical evaluation and normal renal function (estimated creatinine clearance of ≥ 80 ml/min). 16 Exclusion criteria for all individuals were: drug or alcohol abuse; recent therapy with an investigational drug; difficult venous access; recent blood donation; gastroparesis; gastrointestinal surgery within 6 months; significant hepatic insufficiency; or cirrhosis. In addition, any of the following was a reason to exclude haemodialysis-dependent patients: serum albumin < 2.5 g/dl; haemoglobin (Hb) < 8 g/dl; lack of a stable drug regimen; or intake of any of the following medications within 7 days prior to the study: corticosteroids, cyclosporine, cholestyramine, ursodiol, probenecid, trimethoprim, metoclopramide, cisapride, dehydrocholic acid, warfarin or nonsteroidal anti-inflammatory drugs other than aspirin (≤ 325 mg/day). Healthy volunteers were excluded if they had used prescription or non-prescription drugs (with the exception of vitamins, oral contraceptives, hormone replacement therapy or paracetamol) within 7 days of the administration of rosiglitazone, or if they had Hb or haematocrit (Hc) levels below the reference range at screening (Hb, 12.9 -17.1 g/dl; Hc, 32.3 -45%).
DOSING REGIMEN
Healthy volunteers received a single 8-mg oral dose (two 4-mg tablets) of rosiglitazone in a single study session. Haemodialysis-dependent volunteers received a single 8-mg oral dose (two 4-mg tablets) of rosiglitazone on each of two study sessions separated by a washout period of at least 7 days. On the first study day, rosiglitazone was administered approximately 4 h after completion of haemodialysis (nondialysis day). On the second study day, it was administered approximately 3 h before haemodialysis (dialysis day).
On the dialysis day, concomitant medications were withheld from midnight on the preceding night until 5 h after rosiglitazone administration. On the nondialysis day, patients were allowed to take the morning dose of any permitted concomitant medications but subsequent doses were withheld until 5 h after dosing. However, insulin, erythropoietin and 1,25dihydroxyvitamin D were administered according to the patient's usual schedule.
All participants were instructed to abstain from xanthine-containing drinks and foods, alcohol and strenuous physical exercise or exertion for 24 h prior to the study, and for 42 h after rosiglitazone administration.
PATIENT ASSESSMENT
All individuals were screened within 30 days of enrolment into the study to confirm that they met the entrance criteria. Screening included a complete medical history, medication history, physical examination and standard 12-lead electrocardiogram. Vital signs (blood pressure and pulse rate) were measured at baseline, and then again at 4 h and 24 h after rosiglitazone administration. Electrocardiographic data were measured at baseline and 24 h after dosing. Standard haematology, blood chemistry and urine safety laboratory tests were performed at screening and after collection of the last pharmacokinetic sample.
PHARMACOKINETIC BLOOD SAMPLING AND ANALYTICAL METHODOLOGY
In healthy volunteers and patients on the non-dialysis day, blood samples (approximately 5 ml) were collected for pharmacokinetic analysis prior to dose administration, and at 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 8 h, 10 h, 12 h, 16 h, 24 h and 42 h after dosing. An additional 15-ml blood sample was collected from each individual approximately 2 h after dosing for ex vivo proteinbinding analysis.
On the dialysis day, samples were collected prior to dosing, and at 0.5 h, 1 h, 1.5 h, 2 h, 3 h, 7 h, 8 h, 9 h, 11 h, 16 h, 24 h and 46 -48 h after dosing to accommodate haemodialysis. In addition, 15-ml samples were collected for ex vivo protein-binding analysis approximately 2 h and 7 h after dosing, and samples were drawn from the dialyser input (arterial) and output (venous) lines at 3.9 h, 4.9 h, 5.9 h and 6.9 h. Aliquots of dialyser effluent were collected before the start of dialysis treatment and for four successive 1-h periods during dialysis. Blood samples were collected in ethylenediaminotetra-acetic acid tubes and chilled until centrifugation. Separated plasma and dialysate samples were frozen at approximately -20°C.
Plasma and dialysate samples for pharmacokinetic analysis were analysed using Automated Sequential Trace Enrichment of Dialysates (ASTED™, Gilson, Villiers-le-Bel, France) coupled to reverse-phase highperformance liquid chromatography with fluorescence detection. 13 The lower limit of quantification (LLQ) for rosiglitazone was 5 ng/ml for plasma (using a 200-µl plasma aliquot) and 50 pg/ml for dialysate (using a 4-ml dialysate aliquot), with linearity demonstrated up to 1000 ng/ml. Within-day precision was 3.2 -8.9%, between-day precision 3.1 -13.1% and assay accuracy 98.6 -107.1% across the assay range.
The ex vivo protein binding of rosiglitazone was determined using ultrafiltration to separate unbound drug. Triplicate 1-ml aliquots from each plasma K Thompson-Culkin, B Zussman, AK Miller et al.
Rosiglitazone in end-stage renal disease sample (taken 2 h and/or 7 h post-dose) were centrifuged in ultrafiltration apparatus (Centrifree™ micropartition systems, Amicon, Beverly, MA, USA) to obtain ultrafiltrates containing unbound drug. The plasma and ultrafiltrate samples were then assayed using protein precipitation followed by liquid chromatography/mass spectrometry/ mass spectrometry with positive-ion electrospray ionization. The LLQ was 0.25 ng/ml for a sample volume of 50 µl. The assay was calibrated over a concentration range of 2.5 -1000 ng/ml. Unbound concentrations were too low for accurate quantification in approximately half the ultrafiltrate samples. Subsequent assay development led to no further improvement in the LLQ.
Pharmacokinetic parameters for rosiglitazone were determined by noncompartmental methods using a validated in-house software program. Maximum observed plasma concentration (C max ) and its time of first occurrence (t max ) were obtained by inspection. The area under the plasma concentration-time curve between 0 and t h, the time of the last quantifiable concentration (AUC (0 -t) ), was calculated using a combined linear-logarithmic trapezoidal method. The terminal phase rate constant (λ z ) was determined using unweighted linear regression analysis (after log-transformation) on those concentration-time pairs occurring after the visually assessed onset of the terminal loglinear phase. Terminal phase half-life (t 1/2 ) was calculated as the ratio ln 2/λ z . The area under the plasma concentration-time curve between 0 h and infinity (AUC (0 -∞ ) ) was determined as the sum of AUC (0 -t) and the extrapolated area AUC (t -∞ ) , given by the ratio Ct pred /λ z , where Ct pred was the concentration at time t as predicted by the regression analysis.
The total recovery of rosiglitazone in dialyser effluent (A hd ) during the 4-h haemodialysis session was determined by summation of individual recoveries during the four successive 1-h collection periods. The apparent dialytic clearance of rosiglitazone (CL hd ) was calculated as A hd /AUC hd , where AUC hd was the area under the plasma concentration-time curve during the dialysis period.
ADVERSE-EVENT MONITORING
Adverse events were elicited by direct inquiry using non-leading questions. Clinically significant changes in vital signs, electrocardiographic data or laboratory values were also recorded.
STATISTICAL ANALYSIS
Following log e transformation, C max and AUC (0 -∞ ) were analysed separately by analysis of variance appropriate to the study design. Point estimates and associated 95% confidence intervals (CIs) for the difference between haemodialysis-dependent patients on their non-dialysis day and healthy volunteers were calculated based on the residual variance, and then exponentially back-transformed to provide estimates of the ratio of non-dialysis day patient values to healthy volunteer values.
Results
PATIENT DEMOGRAPHICS
Twenty individuals, 10 haemodialysisdependent patients and 10 healthy volunteers, were enrolled in the study. The two populations were adequately matched for age, weight and gender distribution but not for race ( Table 1) . All individuals completed the study.
PHARMACOKINETIC EVALUATION
There were no pronounced differences between the mean rosiglitazone plasma concentration-time profiles of healthy volunteers and haemodialysis-dependent patients (Fig. 1 ). Furthermore, in patients with ESRD, there was no marked difference between the dialysis and non-dialysis concentration profiles. On the dialysis day, there were no sudden discontinuities in plasma concentration-time profiles at the start or end Values are mean ± SD, apart from t max , which is median (range). a Presented as ratio of geometric means for AUC (0 -∞) and C max , mean difference for t 1/2 and median difference for t max (all comparisons are patients on the non-dialysis day versus healthy volunteers). b All AUC (0 -∞) values included ≤ 6% extrapolated area. CI, confidence intervals; AUC (0 -∞) , area under the plasma concentration-time curve between 0 h and infinity; C max , maximum observed plasma concentration; t 1/2 , terminal phase half-life; t max , time of first occurrence of maximum observed plasma concentration.
of dialysis (nominally 3 -7 h after dosing), suggesting that haemodialysis did not markedly influence the pharmacokinetics of rosiglitazone in this group of patients. Plasma concentrations measured in the dialyser input and output lines were very similar throughout the dialysis treatment, with only a small increase of < 10% observed in the output lines compared with the input lines. In addition, < 0.2 mg of the total 8-mg dose (< 2.5%) of rosiglitazone was recovered in the dialyser effluent. Plasma concentrations of rosiglitazone generally rose rapidly after dosing. There were instances of delayed and/or slowed absorption in two healthy volunteers and four haemodialysis-dependent patients, but the impact of these differences on the mean estimates of C max , t max and AUC (0 -∞ ) is believed to have been minimal.
Mean values of the primary pharmacokinetic endpoints (C max and AUC (0 -∞ ) ) were approximately 10% lower in the patient group than in healthy volunteers ( Table 2 ). The ranges of individual C max and AUC (0 -∞ ) SD values in healthy volunteers and haemodialysis-dependent patients (on their non-dialysis day), and the 95% CIs around the geometric means overlapped extensively between groups. Average values of t max and t 1/2 were similar between the two groups; the broad 95% CI for t max reflects the wide dispersion of these data across individuals.
C max and AUC (0 -∞ ) values in the haemodialysis-dependent patients were not markedly influenced by the haemodialysis procedure ( Table 2) . A small reduction in t 1/2 of approximately 20% was indicated, but the resulting reduction in mean AUC (0 -∞ ) was only 10%. Less than 2.5% of the dose was recovered in the dialysate during the 4-h treatment session; therefore, the dialytic clearance was low (mean, 0.10 l/h; range, 0.07 -0.17 l/h).
Residual variability was 33.0% for C max and 24.8% for AUC (0 -∞ ) , indicating no inadequacy in terms of sample size in this study.
Quantification of unbound plasma concentrations in the majority of plasma samples was unsuccessful owing to technical difficulties with the analysis of the plasma ultrafiltrates. Where measurable, the K Thompson-Culkin, B Zussman, AK Miller et al.
Rosiglitazone in end-stage renal disease percentage of unbound rosiglitazone was 0.078 -0.114% in healthy individuals (n = 3) and 0.109 -0.213% in haemodialysisdependent patients (n = 4). The data are too sparse to derive meaningful estimates of unbound AUC (0 -∞ ) and C max , or to attempt formal statistical comparison.
ADVERSE EVENTS
Following treatment with study medication, adverse events occurred in two healthy individuals (dry mouth in one volunteer and palpitation in another) and three haemodialysis patients (gout in one patient, headache in one, and hypotension and syncope in one). None of these events was considered by the investigator to be related to study medication. One haemodialysis patient experienced two serious adverse events (hypotension and syncope) 9 days after dosing, which were thought to be related to the effects of anti-hypertensive medication and excessive ultrafiltration during the preceding haemodialysis session. This patient subsequently completed the second study session without incident. There were no withdrawals because of adverse events.
Discussion
No clinically important pharmacokinetic differences were evident between healthy volunteers and haemodialysis-dependent patients (non-dialysis day) after a single oral 8-mg dose of rosiglitazone. This was not unexpected because rosiglitazone is metabolized extensively in the liver. 15 A single oral dose of rosiglitazone was well tolerated and had a good safety profile both in haemodialysis-dependent patients and healthy volunteers. While the two treatment groups were not balanced by race, this imbalance was not thought to have biased the study findings as racial origin does not significantly influence the pharmacokinetics or pharmacodynamics of rosiglitazone (A Miller, personal communication, 2001 ). Furthermore, this study reported pharmacokinetic parameters similar to those reported previously in an investigation of the pharmacokinetics of rosiglitazone in patients with severe renal impairment, who were predominantly white. 17 These results corroborate observations from a study of the pharmacokinetics of rosiglitazone in patients with mild, moderate and severe renal insufficiency (not requiring haemodialysis), which found small, clinically insignificant differences between healthy patients and patients with renal insufficiency. 17 In that study, observed reductions in C max and AUC (0 -∞ ) were partly explained by an approximately 30% increase in the unbound fraction of rosiglitazone in patients with severe renal impairment who had lower plasma albumin concentrations, resulting in increases in volume of distribution and hepatic clearance. Hepatic clearance of rosiglitazone is primarily dependent on intrinsic clearance of unbound drug and fraction unbound. 18 The unbound AUC (0 -∞ ) of patients in the present study was similar to that of the patients with severe renal impairment. In addition, although protein-binding data were incomplete in the present study, the values observed in haemodialysis-dependent patients were no higher than those in nonend-stage patients with severe renal insufficiency. Therefore, while severe renal insufficiency does reduce the plasma protein binding of rosiglitazone, possibly due to displacement from binding sites by endogenous substances and/or circulating metabolites that accumulate in renal disease, an increase in hepatic clearance occurs that is concomitant to a reduction in total AUC (0 -∞ ) . 8 K Thompson-Culkin, B Zussman, AK Miller et al.
Rosiglitazone in end-stage renal disease
Haemodialysis had no noticeable effect on the AUC (0 -∞ ) of rosiglitazone, which is as expected for a highly protein-bound drug. The dialytic clearance was very low (0.1 l/h), and < 2.5% of the dose was removed during the entire 4-h procedure. Accordingly, plasma concentrations changed little between the input and output lines, with a consistent small increase (< 10%) being attributable to volume changes caused by ultrafiltration or by the movement of water during the haemodialysis period. The average 20% reduction in t 1/2 observed on the dialysis day is not likely to be significant. Therefore, a dosage supplement after dialysis is not warranted, and rosiglitazone can be administered without regard to timing of the dialysis treatment.
The safety profiles of single oral doses of rosiglitazone in both healthy individuals and haemodialysis-dependent patients were unremarkable. 
